Strupp Michael, Feil Katharina, Bardins Stanislavs, Waidelich Raphaela
Department of Neurology, University Hospital Munich, Campus Grosshadern, Munich, Germany. ; German Center for Vertigo and Balance Disorders, University Hospital Munich, Campus Grosshadern, Munich, Germany.
German Center for Vertigo and Balance Disorders, University Hospital Munich, Campus Grosshadern, Munich, Germany.
Int Neurourol J. 2014 Dec;18(4):221-5. doi: 10.5213/inj.2014.18.4.221. Epub 2014 Dec 29.
Aminopyridines are potassium channel blockers that increase the excitability of nerve cells and axons; therefore, they are widely used to treat different neurological disorders. Here we present a patient with idiopathic downbeat nystagmus and lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia who was treated with the sustained-release form of 4-aminopyridine (4-AP). During treatment with 4-AP, the LUTS improved. This improvement was monitored by using uroflowmetry and the International Prostate Symptom Score. A significant improvement of symptoms was observed in relation to the voided volume. This included an improved emptying of the bladder without an increase in residual urine. In animal studies, both nonselective K(+) channel blockade and selective voltage-sensitive potassium blockade by 4-AP resulted in increased contraction on rat detrusor strips. To our knowledge, this is the first clinical observation of the mode of action of 4-AP in urological symptoms in humans.
氨基吡啶是钾通道阻滞剂,可增加神经细胞和轴突的兴奋性;因此,它们被广泛用于治疗各种神经系统疾病。在此,我们报告一名患有特发性下跳性眼球震颤和因良性前列腺增生导致的下尿路症状(LUTS)的患者,该患者接受了4-氨基吡啶(4-AP)缓释制剂的治疗。在使用4-AP治疗期间,LUTS有所改善。通过尿流率测定和国际前列腺症状评分对这种改善进行了监测。观察到与排尿量相关的症状有显著改善。这包括膀胱排空改善且残余尿量未增加。在动物研究中,4-AP的非选择性钾通道阻滞和选择性电压敏感性钾通道阻滞均导致大鼠逼尿肌条收缩增加。据我们所知,这是4-AP对人类泌尿系统症状作用方式的首次临床观察。